Shimizu Wataru
Division of Cardiology, Department of Internal Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Intern Med. 2005 Dec;44(12):1224-31. doi: 10.2169/internalmedicine.44.1224.
Brugada syndrome is characterized by ST-segment elevation in the right precordial leads (V1-V3) and an episode of ventricular fibrillation (VF) in the absence of structural heart disease. A number of reports from the world have unveiled the clinical, electrocardiographic, electrophysiologic and prognostic features of Brugada syndrome, and two recent consensus reports have suggested the diagnostic criteria of Brugada syndrome and the risk stratification for the identification of high risk Brugada patients for sudden cardiac death. SCN5A, the gene encoding the alpha subunit of the sodium channel, is the only gene thus far linked to Brugada syndrome; its prognostic value remains unclear. On the other hand, advances in the understanding of the cellular mechanism for Brugada phenotype derived from experimental studies have suggested possibilities for the development of strategies for managing and treating patients with Brugada syndrome. In this review, the recent understanding and knowledge of Brugada syndrome will be updated.
Brugada综合征的特征是右胸前导联(V1-V3)ST段抬高,且在无结构性心脏病的情况下发生室颤(VF)。来自世界各地的许多报告揭示了Brugada综合征的临床、心电图、电生理和预后特征,最近的两份共识报告提出了Brugada综合征的诊断标准以及识别心脏性猝死高危Brugada患者的风险分层。编码钠通道α亚基的基因SCN5A是迄今为止唯一与Brugada综合征相关的基因;其预后价值仍不明确。另一方面,实验研究对Brugada表型细胞机制认识的进展为Brugada综合征患者管理和治疗策略的开发提供了可能性。在这篇综述中,将更新对Brugada综合征的最新认识和知识。